Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib induction therapy in moderate to severe ulcerative colitis
NCT01458951Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of tofacitinib oral solution in ulcerative colitis (UC), sponsored by Pfizer. Started Jun 2012; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01458951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458951.